Efficacy and safety of regdanvimab (CT-P59): a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate coronavirus disease …
A Streinu-Cercel, O Săndulescu… - Open forum …, 2022 - academic.oup.com
Abstract Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus …
A Streinu-Cercel, O Săndulescu… - Open forum …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing activity
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
[PDF][PDF] Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate …
A Streinu-Cercel, O Săndulescu… - Open Forum …, 2022 - academic.oup.com
Abstract Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus …
A Streinu-Cercel, O Sandulescu, LL Preotescu, JY Kim… - 2022 - scholarworks.bwise.kr
Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing activity
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
[HTML][HTML] Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate …
A Streinu-Cercel, O Săndulescu… - Open Forum …, 2022 - ncbi.nlm.nih.gov
Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing activity
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus …
A Streinu-Cercel, O Săndulescu… - Open Forum …, 2022 - search.ebscohost.com
Abstract Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus …
A Streinu-Cercel, O Săndulescu… - Open Forum …, 2022 - europepmc.org
Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing activity
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
[PDF][PDF] Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate …
A Streinu-Cercel, O Sàndulescu, LL Preotescu, JY Kim… - 2022 - pdfs.semanticscholar.org
Background. Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing activity
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus …
A Streinu-Cercel, O Sandulescu… - Open Forum Infectious …, 2022 - go.gale.com
Background. Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing activity
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus …
A Streinu-Cercel, O Săndulescu… - Open Forum …, 2022 - europepmc.org
Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing activity
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part …